secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2026-09-02T20:11:16+00:00
Accession:  0001193125-26-380194
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences signs 5-year supply deal with Hovione for bezuclastinib manufacturing
--------------------------------------------------------------------------------

- Agreement with Hovione FarmaCiencia S.A. covers bezuclastinib spray-dried dispersion and tablets.
- Initial 5-year term with automatic 2-year renewals; minimum purchase percentages decrease over time.
- Quarterly forecasts; near-term portion binding, balance non-binding good-faith estimates.
- Termination rights include uncured breach, prolonged force majeure, insolvency, regulatory developments.
- Full agreement to be filed with Q3 2026 Form 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/0001193125-26-380194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/d184156d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-380194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer